<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069003</url>
  </required_header>
  <id_info>
    <org_study_id>IP114</org_study_id>
    <nct_id>NCT01069003</nct_id>
  </id_info>
  <brief_title>EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events</brief_title>
  <acronym>EDUCATE</acronym>
  <official_title>EDUCATE: a Prospective, Multi-center Study Designed to Collect Real-world Safety and Clinical Outcomes in Subjects Receiving One or More Endeavor Zotarolimus-Eluting Stents and Either Clopidogrel and Aspirin or Prasugrel and Aspirin as Part of a Dual Antiplatelet Therapy (DAPT) Drug Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EDUCATE is a prospective, multi-center study designed to collect real-world safety and
      clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and
      either clopidogrel and aspirin or prasugrel and aspirin as part of a dual antiplatelet
      therapy (DAPT) drug regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To provide clinical information on rates of late and very late stent thrombosis after
      Endeavor Drug-eluting Stent (DES)placement in an all comers population with a broad range of
      bleeding and thrombosis risk. EDUCATE will further analyze the current practice of clinicians
      regarding temporary cessation of antiplatelet therapy and its association with clinical
      outcomes. In addition, patients included in this broad Endeavor registry will also be
      contributed to the DAPT native study population for analysis of 12 vs 30 months duration of
      dual antiplatelet therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects</measure>
    <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects</measure>
    <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
    <description>All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)
Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers
Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects</measure>
    <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2272</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thienopyridine Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surveillance Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Non randomized subjects followed through 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Arm</intervention_name>
    <description>Placebo and ASA (75 mg - 325 mg)</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thienopyridine Therapy</intervention_name>
    <description>Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)</description>
    <arm_group_label>Thienopyridine Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surveillance Arm</intervention_name>
    <description>Non randomized arm to understand clinical outcomes in a commercial setting</description>
    <arm_group_label>Surveillance Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        ENROLLMENT INCLUSION CRITERIA

          -  Patient is older than 18 years.

          -  The patient or patient's legal representative has consented to participate and has
             authorized the collection and release of his medical information by signing the
             &quot;Subject Informed Consent Form&quot;.

          -  Patients undergoing percutaneous intervention with Endeavor stent deployment (or has
             within 24 hours).

          -  The patient is willing and able to cooperate with study procedures and required follow
             up visits.

        ENROLLMENT EXCLUSION CRITERIA

          -  Index procedure stent placement with stent diameter &lt; 2.5 mm or &gt; 3.5 mm.

          -  Pregnant women.

          -  Current medical condition with a life expectancy of less than 3 years.

          -  The patient is currently participating in another investigational device or drug study
             that clinically interferes with the EDUCATE Study. The patient may only be enrolled in
             the EDUCATE Study once.

          -  Patients with hypersensitivity or allergies to one of the drugs or components
             indicated in the Instructions for Use.

          -  Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.

          -  Patients treated with any stent other than the Endeavor stent during the index
             procedure.

        RANDOMIZATION INCLUSION CRITERIA AT 12 MONTHS

          -  Subject is &quot;12 Month Clear&quot;.

          -  Subjects without known contraindication to dual antiplatelet therapy for at least 18
             months after randomization.

        RANDOMIZATION EXCLUSION CRITERIA AT 12 MONTHS

          -  Pregnant women.

          -  Subject switched thienopyridine type or dose within 6 months prior to randomization.

          -  Planned surgery necessitating discontinuation of antiplatelet therapy within the 18
             months following randomization.

          -  Percutaneous coronary intervention or cardiac surgery between 6 weeks post index
             procedure and randomization.

          -  Planned surgery necessitating discontinuation of antiplatelet therapy within the 21
             months following randomization.

          -  Current medical condition with a life expectancy of less than 3 years.

          -  Subjects on warfarin or similar anticoagulant therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Cutlip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold Dauerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fletcher Allen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AnMed Health Medical Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.daptstudy.org/</url>
    <description>Native DAPT Study Web Site</description>
  </link>
  <link>
    <url>http://www.hcri.harvard.edu/</url>
    <description>Harvard Clinical Research Institute</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <results_first_submitted>June 29, 2015</results_first_submitted>
  <results_first_submitted_qc>December 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <last_update_submitted>December 11, 2015</last_update_submitted>
  <last_update_submitted_qc>December 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Platelet Aggregation Inhibitors</keyword>
  <keyword>Dual Antiplatelet Therapy</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Prasugrel</keyword>
  <keyword>Vascular Disease</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled 2272 but only 2262 subjects were analysis receiving the Endeavor stent only.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="P2">
          <title>Thienopyridine Therapy</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="P3">
          <title>Surveillance Arm</title>
          <description>Non randomized subjects followed for total of 24 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="399"/>
                <participants group_id="P2" count="412"/>
                <participants group_id="P3" count="1451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="353"/>
                <participants group_id="P2" count="358"/>
                <participants group_id="P3" count="976"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="475"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The intent to treat arm contains non randomized subjects followed through 24 months</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Arm</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="B2">
          <title>Thienopyridine Therapy</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="B3">
          <title>Surveillance Arm</title>
          <description>Non randomized subjects followed for total of 24 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="399"/>
            <count group_id="B2" value="412"/>
            <count group_id="B3" value="1451"/>
            <count group_id="B4" value="2262"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="10.7"/>
                    <measurement group_id="B2" value="62.5" spread="10.7"/>
                    <measurement group_id="B3" value="64.6" spread="11.3"/>
                    <measurement group_id="B4" value="63.3" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="449"/>
                    <measurement group_id="B4" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="277"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="1002"/>
                    <measurement group_id="B4" value="1575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="372"/>
                    <measurement group_id="B2" value="385"/>
                    <measurement group_id="B3" value="1409"/>
                    <measurement group_id="B4" value="2166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects</title>
        <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O2">
            <title>Thienopyridine Therapy</title>
            <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O3">
            <title>Surveillance Arm</title>
            <description>Subjects followed for total of 24 months and not clear for randomization. Subjects who had a death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Composite of All Death, Target Vessel Myocardial Infarction (MI) and Stroke (Defined as MACCE) for Randomized Subjects</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="1451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="4.8"/>
                    <measurement group_id="O3" value="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects</title>
        <description>All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)
Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers
Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
        <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Subjects without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O2">
            <title>Thienopyridine Therapy</title>
            <description>Subjects without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O3">
            <title>Surveillance Arm</title>
            <description>Subjects followed for total of 24 months and not clear for randomization. Subjects who had a death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants of Incidence of ARC Definite or Probable Stent Thrombosis (ST) for Randomized Subjects</title>
          <description>All definite and probable Stent Thrombosis (ST) are adjudicated by an independent committee according to the definition based on Academic Research Consortium (ARC)
Definite is defined as angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region and at least 1 of the following: Acute ischemic symptoms, Ischemic ECG changes, Elevated cardiac biomarkers
Probable defined as any unexplained death within the first 30 days of procedure and any myocardial infarction, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="1451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects</title>
        <time_frame>Placebo and Thienopyridine 12 - 30 months; Surveillance Arm (0 - 24 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O2">
            <title>Thienopyridine Therapy</title>
            <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
          </group>
          <group group_id="O3">
            <title>Surveillance Arm</title>
            <description>Subjects followed for total of 24 months and not clear for randomization. Subjects who had a death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding (GUSTO Classification, Severe and Moderate Bleeding Combined) for Randomized Subjects</title>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="393"/>
                <count group_id="O3" value="1451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All events were collected up to 12 months post procedure and only serous adverse events were collected after 12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Arm</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA).
Placebo (12-Month Arm): Placebo
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="E2">
          <title>Thienopyridine Therapy</title>
          <description>Subjects without death, MI, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months. These subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA).
Prasugrel and Clopidogrel (30-Month Arm): Prasugrel 5 or 10 mg; Clopidogrel 75 mg
ASA: 75 mg - 325 mg Aspirin(ASA)</description>
        </group>
        <group group_id="E3">
          <title>Surveillance Arm</title>
          <description>Non randomized subjects followed through 24 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="399"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="664" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="41" subjects_affected="37" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="59" subjects_affected="55" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="40" subjects_affected="39" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="32" subjects_affected="31" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="399"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="53" subjects_affected="39" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="399"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="21" subjects_affected="15" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="412"/>
                <counts group_id="E3" events="51" subjects_affected="44" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="399"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="412"/>
                <counts group_id="E3" events="128" subjects_affected="97" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="412"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="26" subjects_affected="20" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Thrombosis In Device</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac Enzymes Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="412"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="33" subjects_affected="20" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="399"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="412"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Therapeutic Embolisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="412"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="412"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="1451"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" subjects_affected="90" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="399"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="412"/>
                <counts group_id="E3" events="96" subjects_affected="90" subjects_at_risk="1451"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sidney Cohen, Sr. Clinical Medical Advisor</name_or_title>
      <organization>Medtronic</organization>
      <phone>707-591-7277</phone>
      <email>sidney.a.cohen@medtonic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

